

Parexel, NeoGenomics to advance precision medicine in oncology clinical trials

11 February 2021 | News

The collaboration with NeoGenomics will enhance Parexel's use of real-world data across various applications, including identifying and estimating prevalence of genomic mutations within respective populations



Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health and NeoGenomics, Inc, a leading provider of cancer-focused genetic testing services and global oncology contract research services, have announced a strategic partnership to advance the application of precision medicine in oncology clinical trials by applying real-world genomics data to accelerate patient matching and optimise trial design, site selection, clinical development and translational research.

The collaboration with NeoGenomics will enhance Parexel's use of real-world data across various applications, including identifying and estimating prevalence of genomic mutations within respective populations, genomic patterning to stratify patients according to novel biomarkers, and use of de-identified patient data to precisely target patient populations.

"Parexel's partnership with NeoGenomics provides access to greater predictive modelling capabilities so that we can rapidly identify specific patients and connect them to clinical trials that provide them with the best potential for treatment, advance our understanding of their disease and identify the drug's effects and potential benefits," said Sy Pretorius, MD, President, Clinical Development and Chief Medical Officer, Parexel.

"We are thrilled to collaborate with Parexel to provide our robust genomic and clinical database to help match cancer patients to clinical trials and therapies that are precisely targeted to their unique tumour types and genomic biomarkers," said Douglas VanOort, Chairman and Chief Executive Officer, NeoGenomics.

The companies are considering potential opportunities to expand the scope of the partnership, including lab services and biomarker capabilities.